阴道孕酮能否预防有自发早产史的单胎妊娠妇女复发性早产?系统综述与Meta分析的证据
该系统综述与Meta分析纳入10项随机对照试验共2958例有自发早产史的单胎妊娠无症状妇女,评估阴道孕酮预防复发性早产及不良围产结局的疗效与安全性。总体分析显示阴道孕酮可降低早产<37周和<34周风险及新生儿重症监护病房入住风险,但证据质量很低;限制于低偏倚风险研究的敏感性分析及小样本效应校正后,上述获益不再显著。结论认为无令人信服的证据支持使用阴道孕酮预防复发性早产或改善围产结局。
要点
- 总体分析显示阴道孕酮降低早产<37周(RR 0.64)和<34周(RR 0.62)风险,但证据质量很低。
- 限制于低偏倚风险研究的敏感性分析中,阴道孕酮未降低早产<37周(RR 0.96)和<34周(RR 0.90)风险。
- 小样本效应校正后阴道孕酮对早产<37周(RR 0.86)和<34周(RR 0.92)的效应不再显著。
核心结论
- 无令人信服的证据支持使用阴道孕酮预防有自发早产史的单胎妊娠妇女的复发性早产或改善围产结局。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、LILACS、CINAHL(自建库至2022年2月28日)、Cochrane数据库、Google Scholar、参考文献目录及会议论文集。
- 纳入比较阴道孕酮与安慰剂或无治疗的有自发早产史单胎妊娠无症状妇女的随机对照试验,共10项研究2958例妇女。
- 10项研究中7项样本量<150(小样本研究),3项样本量>600(大样本研究)。
- 7项小样本研究中4项高偏倚风险、2项存在一些偏倚担忧、仅1项低偏倚风险;所有大样本研究均为低偏倚风险。
- 计算合并相对危险度及95%置信区间,评估偏倚风险、异质性(I²检验)、小样本效应、发表偏倚及证据质量,并进行亚组分析、敏感性分析、95%预测区间及校正相对危险度。
主要发现
- 阴道孕酮显著降低早产<37周风险(RR 0.64,95%CI 0.50-0.81;I²=75%;95%预测区间0.31-1.32;极低质量证据)和<34周风险(RR 0.62,95%CI 0.42-0.92;I²=66%;95%预测区间0.23-1.68;极低质量证据)。
- 阴道孕酮显著降低新生儿重症监护病房入住风险(RR 0.53,95%CI 0.33-0.85;I²=67%;95%预测区间0.16-1.79;低质量证据)。
- 阴道孕酮组与安慰剂或无治疗组在其他不良围产结局和母体结局方面无显著差异。
- 亚组分析显示小样本研究中阴道孕酮降低早产<37周风险(RR 0.43,95%CI 0.33-0.55;I²=0%)和<34周风险(RR 0.27,95%CI 0.15-0.49;I²=0%),大样本研究中未见降低(早产<37周RR 0.98,95%CI 0.88-1.09;I²=0%;早产<34周RR 0.94,95%CI 0.78-1.13;I²=0%)。
- 限制于低偏倚风险研究的敏感性分析显示阴道孕酮未降低早产<37周风险(RR 0.96,95%CI 0.84-1.09)和<34周风险(RR 0.90,95%CI 0.71-1.15)。
临床怎么用
- 原文结论认为无令人信服的证据支持使用阴道孕酮预防有自发早产史的单胎妊娠妇女的复发性早产或改善围产结局。
局限性
- 7项小样本研究(样本量<150)中4项高偏倚风险、2项存在一些偏倚担忧、仅1项低偏倚风险。
- 早产<37周分析异质性I²=75%,早产<34周分析异质性I²=66%,新生儿重症监护病房入住分析异质性I²=67%。
- 早产<37周和<34周的Meta分析中存在明显的小样本效应证据,表现为漏斗图不对称及固定效应与随机效应模型合并相对危险度显著差异。
- 总体分析证据质量极低(早产<37周和<34周)或低(新生儿重症监护病房入住)。
- 限制于低偏倚风险研究的敏感性分析及小样本效应校正后,阴道孕酮的效应不再显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of vaginal progesterone to prevent recurrent preterm birth and adverse perinatal outcomes in singleton gestations with a history of spontaneous preterm birth. DATA SOURCES: MEDLINE, Embase, LILACS, and CINAHL (from their inception to February 28, 2022), Cochrane databases, Google Scholar, bibliographies, and conference proceedings. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials that compared vaginal progesterone to placebo or no treatment in asymptomatic women with a singleton gestation and a history of spontaneous preterm birth. METHODS: The primary outcomes were preterm birth <37 and <34 weeks of gestation. The secondary outcomes included adverse maternal and perinatal outcomes. Pooled relative risks with 95% confidence intervals were calculated. We assessed the risk of bias in the included studies, heterogeneity (I2 test), small-study effects, publication bias, and quality of evidence; performed subgroup and sensitivity analyses; and calculated 95% prediction intervals and adjusted relative risks. RESULTS: Ten studies (2958 women) met the inclusion criteria: 7 with a sample size <150 (small studies) and 3 with a sample size >600 (large studies). Among the 7 small studies, 4 were at high risk of bias, 2 were at some concerns of bias, and only 1 was at low risk of bias. All the large studies were at low risk of bias. Vaginal progesterone significantly decreased the risk of preterm birth <37 weeks (relative risk, 0.64; 95% confidence interval, 0.50-0.81; I2=75%; 95% prediction interval, 0.31-1.32; very low-quality evidence) and <34 weeks (relative risk, 0.62; 95% confidence interval, 0.42-0.92; I2=66%; 95% prediction interval, 0.23-1.68; very low-quality evidence), and the risk of admission to the neonatal intensive care unit (relative risk, 0.53; 95% confidence interval, 0.33-0.85; I2=67%; 95% prediction interval, 0.16-1.79; low-quality evidence). There were no significant differences between the vaginal progesterone and the placebo or no treatment groups in other adverse perinatal and maternal outcomes. Subgroup analyses revealed that vaginal progesterone decreased the risk of preterm birth <37 weeks (relative risk, 0.43; 95% confidence interval, 0.33-0.55; I2=0%) and <34 weeks (relative risk, 0.27; 95% confidence interval, 0.15-0.49; I2=0%) in the small but not in the large studies (relative risk, 0.98; 95% confidence interval, 0.88-1.09; I2=0% for preterm birth <37 weeks; and relative risk, 0.94; 95% confidence interval, 0.78-1.13; I2=0% for preterm birth <34 weeks). Sensitivity analyses restricted to studies at low risk of bias indicated that vaginal progesterone did not reduce the risk of preterm birth <37 weeks (relative risk, 0.96; 95% confidence interval, 0.84-1.09) and <34 weeks (relative risk, 0.90; 95% confidence interval, 0.71-1.15). There was clear evidence of substantial small-study effects in the meta-analyses of preterm birth <37 and <34 weeks of gestation because of funnel plot asymmetry and the marked differences in the pooled relative risks obtained from fixed-effect and random-effects models. The adjustment for small-study effects resulted in a markedly reduced and nonsignificant effect of vaginal progesterone on preterm birth <37 weeks (relative risk, 0.86; 95% confidence interval, 0.68-1.10) and <34 weeks (relative risk, 0.92; 95% confidence interval, 0.60-1.42). CONCLUSION: There is no convincing evidence supporting the use of vaginal progesterone to prevent recurrent preterm birth or to improve perinatal outcomes in singleton gestations with a history of spontaneous preterm birth.
引用
- Conde-Agudelo A, Romero R. Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis. Am J Obstet Gynecol. 2022. PMID: 35460628. doi:10.1016/j.ajog.2022.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。